| vildagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs glimepiride (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.58 [0.29 1.14] | p=1.00 | 0 | 771 | 1 | Schweizer, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs pioglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.95 [0.37 2.44] | p=1.00 | 0 | 576 | 1 | Bolli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 2.24 [0.84 6.00] | p=1.00 | 0 | 306 | 1 | Scherbaum [2], |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on current therapy) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on glimepiride) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on insulin) | No demonstrated result Adverse events leading to treatment discontinuation by 850% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 9.50 [1.19 75.97] | p=0.04 | 0 | 296 | 1 | Fonseca, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.63 [0.50 5.36] | p=1.00 | 0 | 471 | 2 | Ahren,Bosi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on SU) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.47 [0.14 1.55] | p=1.00 | 0 | 314 | 1 | Rosenstock** (vilda + pio vs pio), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (on top pioglitazone) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.25 [0.33 4.74] | p=1.00 | 0 | 316 | 1 | Garber, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs rosiglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs Sulfonylurea (add on to MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs TZD (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs voglibose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin + MET vs MET | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs acarbose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs gliclazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.59 [0.75 3.39] | p=1.00 | 0 | 711 | 4 | Dejager [1],Pi-Sunyer,Pratley,Ristic, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All types of patients: 43 trials - Dejager [1] - Mimori - Pi-Sunyer - Pratley - Ristic - Scherbaum [2] - Rosenstock* (vilda vs rosi) - Rosenstock** (vilda vs pio) - Schweizer - Ahren - Bolli - Bosi - Fonseca - Garber - Rosenstock** (vilda + pio vs pio) - Ferrannini - Goodman - Filozof - Goke - Foley - Pan - Rosenstock - Schweizer - Bosi - Garber - NCT00101673 - Foley - GALIANT (Blonde) - Kikuchi - CLAF237A 23104 - NCT00728351 - Kikuchi - NCT00822211 - NCT00368134 - NCT00351832 - NCT00494884 (Wollmer) - Ahren - NCT00396071 - Rosenstock - Lukashevich - Matthews - Iwamoto - Fonseca
| vildagliptin vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs glimepiride (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs metformin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.58 [0.29 1.14] | p=1.00 | 0 | 771 | 1 | Schweizer, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs pioglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.95 [0.37 2.44] | p=1.00 | 0 | 576 | 1 | Bolli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 2.24 [0.84 6.00] | p=1.00 | 0 | 306 | 1 | Scherbaum [2], |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on current therapy) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on glimepiride) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on insulin) | No demonstrated result Adverse events leading to treatment discontinuation by 850% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 9.50 [1.19 75.97] | p=0.04 | 0 | 296 | 1 | Fonseca, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.63 [0.50 5.36] | p=1.00 | 0 | 471 | 2 | Ahren,Bosi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on SU) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.47 [0.14 1.55] | p=1.00 | 0 | 314 | 1 | Rosenstock** (vilda + pio vs pio), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (on top pioglitazone) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.25 [0.33 4.74] | p=1.00 | 0 | 316 | 1 | Garber, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs rosiglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs Sulfonylurea (add on to MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs TZD (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs voglibose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin + MET vs MET | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs acarbose | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs gliclazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin monotherapy vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.59 [0.75 3.39] | p=1.00 | 0 | 711 | 4 | Dejager [1],Pi-Sunyer,Pratley,Ristic, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 5 trials - Ahren - Bolli - Bosi - Ferrannini - Goodman
| vildagliptin vs pioglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.95 [0.37 2.44] | p=1.00 | 0 | 576 | 1 | Bolli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.63 [0.50 5.36] | p=1.00 | 0 | 471 | 2 | Ahren,Bosi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs Sulfonylurea (add on to MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 8 trials - Ahren - Bolli - Bosi - Fonseca - Garber - Rosenstock** (vilda + pio vs pio) - Ferrannini - Goodman
| vildagliptin vs pioglitazone (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.95 [0.37 2.44] | p=1.00 | 0 | 576 | 1 | Bolli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on insulin) | No demonstrated result Adverse events leading to treatment discontinuation by 850% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 9.50 [1.19 75.97] | p=0.04 | 0 | 296 | 1 | Fonseca, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.63 [0.50 5.36] | p=1.00 | 0 | 471 | 2 | Ahren,Bosi, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.47 [0.14 1.55] | p=1.00 | 0 | 314 | 1 | Rosenstock** (vilda + pio vs pio), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (on top pioglitazone) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.25 [0.33 4.74] | p=1.00 | 0 | 316 | 1 | Garber, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs Sulfonylurea (add on to MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on TZD: 2 trials - Garber - Rosenstock** (vilda + pio vs pio)
| vildagliptin vs placebo (add on TZD) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.47 [0.14 1.55] | p=1.00 | 0 | 314 | 1 | Rosenstock** (vilda + pio vs pio), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| vildagliptin vs placebo (on top pioglitazone) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 1.25 [0.33 4.74] | p=1.00 | 0 | 316 | 1 | Garber, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled with insulin: 1 trials - Fonseca
| vildagliptin vs placebo (add on insulin) | No demonstrated result Adverse events leading to treatment discontinuation by 850% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | 9.50 [1.19 75.97] | p=0.04 | 0 | 296 | 1 | Fonseca, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
